Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors

Zhaoju Wu, Pei Ching Chang, Joy C. Yang, Cheng Ying Chu, Ling Yu Wang, Nien Tsu Chen, Ai Hong Ma, Sonal J. Desai, Su Hao Lo, Christopher P. Evans, Kit S Lam, Hsing Jien Kung

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

There is overwhelming evidence that tyrosine kinases play an important role in cancer development. As a prototype of targeted therapy, tyrosine kinase inhibitors are now successfully applied to cancer treatment. However, as single agents, tyrosine kinase inhibitors have not achieved satisfactory results in the treatment of prostate cancer, principally due to their inability to efficiently kill tumor cells. The authors' laboratory has been interested in the role of the Src complex in prostate cancer progression, including the induction of androgen independence and metastasis. Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis. Here, they have shown that Src family kinase (SFK) inhibitors can induce a high level of autophagy, which protects treated cells from undergoing apoptosis. Src siRNA knockdown experiments confirmed that autophagy was indeed caused by the lack of Src activity. The SFK inhibitor-induced autophagy is accompanied by the inhibition of the PI3K (type I)/Akt/mTOR signaling pathway. To test whether autophagy blockade could lead to enhanced cell death, pharmacological inhibitors (3-methyladenine and chloroquine) and a genetic inhibitor (siRNA targeting Atg7) were used in combination with SFK inhibitors. The results showed that autophagy inhibition effectively enhanced cell killing induced by SFK inhibitors. Importantly, the authors showed that a combination of saracatinib with chloroquine in mice significantly reduced prostate cancer (PC3) xenograft growth compared with the control group. Taken together, these data suggest that (1) autophagy serves a protective role in SFK inhibitor-mediated cell killing, and (2) clinically acceptable autophagy modulators may be used beneficially as adjunctive therapeutic agents for SFK inhibitors.

Original languageEnglish
Pages (from-to)40-49
Number of pages10
JournalGenes and Cancer
Volume1
Issue number1
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

src-Family Kinases
Autophagy
Prostatic Neoplasms
Protein-Tyrosine Kinases
Chloroquine
Small Interfering RNA
Apoptosis
Neoplasms
Growth
Phosphatidylinositol 3-Kinases
Heterografts
Androgens
Cell Death
Pharmacology
Neoplasm Metastasis
Control Groups
Therapeutics

Keywords

  • Autophagy
  • Chloroquine
  • Prostate cancer
  • Saracatinib
  • Src tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors. / Wu, Zhaoju; Chang, Pei Ching; Yang, Joy C.; Chu, Cheng Ying; Wang, Ling Yu; Chen, Nien Tsu; Ma, Ai Hong; Desai, Sonal J.; Lo, Su Hao; Evans, Christopher P.; Lam, Kit S; Kung, Hsing Jien.

In: Genes and Cancer, Vol. 1, No. 1, 2010, p. 40-49.

Research output: Contribution to journalArticle

Wu, Z, Chang, PC, Yang, JC, Chu, CY, Wang, LY, Chen, NT, Ma, AH, Desai, SJ, Lo, SH, Evans, CP, Lam, KS & Kung, HJ 2010, 'Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors', Genes and Cancer, vol. 1, no. 1, pp. 40-49. https://doi.org/10.1177/1947601909358324
Wu, Zhaoju ; Chang, Pei Ching ; Yang, Joy C. ; Chu, Cheng Ying ; Wang, Ling Yu ; Chen, Nien Tsu ; Ma, Ai Hong ; Desai, Sonal J. ; Lo, Su Hao ; Evans, Christopher P. ; Lam, Kit S ; Kung, Hsing Jien. / Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors. In: Genes and Cancer. 2010 ; Vol. 1, No. 1. pp. 40-49.
@article{e92762a33fc94dd0a70fbb999367f2bf,
title = "Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors",
abstract = "There is overwhelming evidence that tyrosine kinases play an important role in cancer development. As a prototype of targeted therapy, tyrosine kinase inhibitors are now successfully applied to cancer treatment. However, as single agents, tyrosine kinase inhibitors have not achieved satisfactory results in the treatment of prostate cancer, principally due to their inability to efficiently kill tumor cells. The authors' laboratory has been interested in the role of the Src complex in prostate cancer progression, including the induction of androgen independence and metastasis. Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis. Here, they have shown that Src family kinase (SFK) inhibitors can induce a high level of autophagy, which protects treated cells from undergoing apoptosis. Src siRNA knockdown experiments confirmed that autophagy was indeed caused by the lack of Src activity. The SFK inhibitor-induced autophagy is accompanied by the inhibition of the PI3K (type I)/Akt/mTOR signaling pathway. To test whether autophagy blockade could lead to enhanced cell death, pharmacological inhibitors (3-methyladenine and chloroquine) and a genetic inhibitor (siRNA targeting Atg7) were used in combination with SFK inhibitors. The results showed that autophagy inhibition effectively enhanced cell killing induced by SFK inhibitors. Importantly, the authors showed that a combination of saracatinib with chloroquine in mice significantly reduced prostate cancer (PC3) xenograft growth compared with the control group. Taken together, these data suggest that (1) autophagy serves a protective role in SFK inhibitor-mediated cell killing, and (2) clinically acceptable autophagy modulators may be used beneficially as adjunctive therapeutic agents for SFK inhibitors.",
keywords = "Autophagy, Chloroquine, Prostate cancer, Saracatinib, Src tyrosine kinase",
author = "Zhaoju Wu and Chang, {Pei Ching} and Yang, {Joy C.} and Chu, {Cheng Ying} and Wang, {Ling Yu} and Chen, {Nien Tsu} and Ma, {Ai Hong} and Desai, {Sonal J.} and Lo, {Su Hao} and Evans, {Christopher P.} and Lam, {Kit S} and Kung, {Hsing Jien}",
year = "2010",
doi = "10.1177/1947601909358324",
language = "English",
volume = "1",
pages = "40--49",
journal = "Genes and Cancer",
issn = "1947-6019",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Autophagy blockade sensitizes prostate cancer cells towards src family kinase inhibitors

AU - Wu, Zhaoju

AU - Chang, Pei Ching

AU - Yang, Joy C.

AU - Chu, Cheng Ying

AU - Wang, Ling Yu

AU - Chen, Nien Tsu

AU - Ma, Ai Hong

AU - Desai, Sonal J.

AU - Lo, Su Hao

AU - Evans, Christopher P.

AU - Lam, Kit S

AU - Kung, Hsing Jien

PY - 2010

Y1 - 2010

N2 - There is overwhelming evidence that tyrosine kinases play an important role in cancer development. As a prototype of targeted therapy, tyrosine kinase inhibitors are now successfully applied to cancer treatment. However, as single agents, tyrosine kinase inhibitors have not achieved satisfactory results in the treatment of prostate cancer, principally due to their inability to efficiently kill tumor cells. The authors' laboratory has been interested in the role of the Src complex in prostate cancer progression, including the induction of androgen independence and metastasis. Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis. Here, they have shown that Src family kinase (SFK) inhibitors can induce a high level of autophagy, which protects treated cells from undergoing apoptosis. Src siRNA knockdown experiments confirmed that autophagy was indeed caused by the lack of Src activity. The SFK inhibitor-induced autophagy is accompanied by the inhibition of the PI3K (type I)/Akt/mTOR signaling pathway. To test whether autophagy blockade could lead to enhanced cell death, pharmacological inhibitors (3-methyladenine and chloroquine) and a genetic inhibitor (siRNA targeting Atg7) were used in combination with SFK inhibitors. The results showed that autophagy inhibition effectively enhanced cell killing induced by SFK inhibitors. Importantly, the authors showed that a combination of saracatinib with chloroquine in mice significantly reduced prostate cancer (PC3) xenograft growth compared with the control group. Taken together, these data suggest that (1) autophagy serves a protective role in SFK inhibitor-mediated cell killing, and (2) clinically acceptable autophagy modulators may be used beneficially as adjunctive therapeutic agents for SFK inhibitors.

AB - There is overwhelming evidence that tyrosine kinases play an important role in cancer development. As a prototype of targeted therapy, tyrosine kinase inhibitors are now successfully applied to cancer treatment. However, as single agents, tyrosine kinase inhibitors have not achieved satisfactory results in the treatment of prostate cancer, principally due to their inability to efficiently kill tumor cells. The authors' laboratory has been interested in the role of the Src complex in prostate cancer progression, including the induction of androgen independence and metastasis. Previously, the authors reported that Src inhibitors such as saracatinib and PP2 caused G1 growth arrest and diminished invasiveness in prostate cancer cells but rarely apoptosis. Here, they have shown that Src family kinase (SFK) inhibitors can induce a high level of autophagy, which protects treated cells from undergoing apoptosis. Src siRNA knockdown experiments confirmed that autophagy was indeed caused by the lack of Src activity. The SFK inhibitor-induced autophagy is accompanied by the inhibition of the PI3K (type I)/Akt/mTOR signaling pathway. To test whether autophagy blockade could lead to enhanced cell death, pharmacological inhibitors (3-methyladenine and chloroquine) and a genetic inhibitor (siRNA targeting Atg7) were used in combination with SFK inhibitors. The results showed that autophagy inhibition effectively enhanced cell killing induced by SFK inhibitors. Importantly, the authors showed that a combination of saracatinib with chloroquine in mice significantly reduced prostate cancer (PC3) xenograft growth compared with the control group. Taken together, these data suggest that (1) autophagy serves a protective role in SFK inhibitor-mediated cell killing, and (2) clinically acceptable autophagy modulators may be used beneficially as adjunctive therapeutic agents for SFK inhibitors.

KW - Autophagy

KW - Chloroquine

KW - Prostate cancer

KW - Saracatinib

KW - Src tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=77953383616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953383616&partnerID=8YFLogxK

U2 - 10.1177/1947601909358324

DO - 10.1177/1947601909358324

M3 - Article

VL - 1

SP - 40

EP - 49

JO - Genes and Cancer

JF - Genes and Cancer

SN - 1947-6019

IS - 1

ER -